←
Bhardwaj Lab713 posts
Bhardwaj Lab avatar

Bhardwaj Lab

@BhardwajLab

@TischCancer @SinaiImmunol Laboratory of Dr. Nina Bhardwaj Immunology & Immunotherapy Posts by Lab Members

◷ Joined April 2021▧ 122 Photos and videos
Bhardwaj Lab avatar
Bhardwaj Lab@BhardwajLab·22h

Farewell dinner for our amazing postdoc Guillaume🥹Thank you for the science and all the good laughs at the bench. We'll miss you so much.

Post attachment
Parker Institute avatar
⟳ Bhardwaj Lab retweeted
Parker Institute@parkerici·Nov 11

Congratulations to PICI researcher @RobertBlelloch, MD, PhD, and his @UCSF colleagues on new research showing how lab-grown dendritic cells can be “dressed” with a patient’s own tumor material to train T cells to target and kill cancer cells. Read more here: cancer.ucsf.edu/news/2026/08…

AACR avatar
⟳ Bhardwaj Lab retweeted
AACR@AACR·Nov 9

Submit an abstract by December 7 for the AACR IO Conference on Discovery and Innovation in Cancer Immunology (February 28-March 3, 2027; Los Angeles), chaired by Nina Bhardwaj, Elizabeth M. Jaffee, and Antoni Ribas. Learn more: brnw.ch/21x70hN #AACRIO27 @BhardwajLab

Post attachment
Aponia_Analytics avatar
⟳ Bhardwaj Lab retweeted
Aponia_Analytics@AponiaAnalytics·Oct 4

🦉The vaccine got T cells in — but mostly not the ones that mattered. CCL21-engineered dendritic cells did what they were designed to do: they pulled new T-cell clones into resistant NSCLC tumors. Yet among 19 evaluable patients there were no objective responses. The more revealing result came later. Many recruited clones disappeared by day 42, while the minority that persisted were more likely to show tumor-reactive signatures and expanded more strongly in patients with stable disease. Meanwhile, suppressive IL1B⁺/SPP1⁺ macrophage signaling remained. That shifts the bottleneck. In a “cold” tumor, getting more T cells through the door may not be enough. Which clones arrive, whether they recognize tumor, and whether the microenvironment lets them survive may matter more than infiltration itself. Small, uncontrolled phase I data, and tumor specificity was inferred rather than directly proven—but the biology is a useful warning against treating T-cell density as a surrogate for effective immunity. #immunotherapy #T_cell #dendritic_cell 👉doi.org/10.1038/s41467-026-7…

Post attachment
Bhardwaj Lab avatar
Bhardwaj Lab@BhardwajLab·Oct 2

Retreat season is here! Next Thursday at the PrIISM-IGI-CVRI Retreat, our postdoc Ross Ward @RossWWard44 is giving a talk in the 10-11 AM Trainee Talks session, and a few of us will be around with posters too. Come find us, we'd love to connect! #PrIISMCVRIIGI2026

Post attachment
AACR avatar
⟳ Bhardwaj Lab retweeted
AACR@AACR·Aug 26

The @US_FDA approved the HER2-targeted therapy zanidatamab plus chemotherapy (with tislelizumab for some patients) as first-line treatment for certain HER2-positive unresectable advanced gastric, gastroesophageal junction, or esophageal cancers: Journals: brnw.ch/21x5dZf